Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Shire Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Designation or determination (3)
Australian Public Assessment Report (AusPAR) (2)
Prescription medicine decision summary (1)

Date

2020 (1)
2019 (2)
2018 (3)

Results for "[search-keyword]"

Search

Sponsor content

6 result(s) found, displaying 1 to 6

Veyvondi

29 April 2020

Prescription medicine decision summary

Australian prescription medicine decision summary
AusPAR: Icatibant (as acetate)

1 November 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Icatibant (as acetate)
Notice for teduglutide (Shire Australia Pty Limited)

26 February 2019

Designation or determination

Orphan drug
AusPAR: Guanfacine

3 May 2018

Australian Public Assessment Report (AusPAR)
Notice for lanadelumab (Shire Australia Pty Limited)

21 February 2018

Designation or determination

Priority review
Notice for lanadelumab (Shire Australia Pty Limited)

21 February 2018

Designation or determination

Orphan drug

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Shire Australia Pty Limited

Type

Date

Veyvondi

AusPAR: Icatibant (as acetate)

Notice for teduglutide (Shire Australia Pty Limited)

AusPAR: Guanfacine

Notice for lanadelumab (Shire Australia Pty Limited)

Notice for lanadelumab (Shire Australia Pty Limited)

Help us improve the Therapeutic Goods Administration site